Please assess the completion status of the following clinical trial:

Trial Title: Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with recurrent squamous cell carcinoma or a second primary arising in a previously irradiated field~* Life expectancy of greater than 6 months~* Patients cannot have distant metastases and have to be candidates for curative re-irradiation~* Patients with salivary gland tumors are excluded (patients with nasopharynx or sinonasal cancers can participate)~* Patients with unresectable disease are eligible~* Patients who undergo surgical resection will be allowed regardless of human papilloma virus (HPV) status provided they have one of the following criteria:~  * Positive margins on pathology~ * Evidence of extracapsular spread on nodal pathology~ * Gross residual disease on postoperative or simulation imaging~ * N2/3 disease~ * T3/4 disease~ * Multifocal perineural invasion and/or lymphovascular space invasion~* The majority of the anticipated target volume (\> 50%) must have been previously treated to ≥ 40 Gy; prior radiation therapy (RT) must have been completed \> 6 months prior to initiation of IMRT reirradiation; if previous RT records are unavailable, investigators can estimate the dose to previously treated tissues based on completion notes or other treatment history~* An Eastern Cooperative Oncology Group (ECOG) performance score 0-2~* Granulocytes \> 1500/mm³~* Platelets \> 100,000/mm³~* Bilirubin \< 1.5 mg/dl~* Creatinine \< 1.5 mg/dl~* No other concurrent invasive malignancies treated for the past year (localized prostate cancer or early stage skin cancer are not exclusion criteria)~* Patients with carotid artery involvement or encasement will be allowed provided they have no symptoms related to carotid involvement~* No prior exposure to immunotherapy agents~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Any known factors that would pose a contraindication to receiving nivolumab~* Recursive partitioning analysis (RPA) class III patients defined as those expected to begin reirradiation within 2 years of first course of radiation therapy AND are percutaneous endoscopic gastrostomy (PEG) dependent or have a tracheostomy (patients who have undergone total laryngectomy are not excluded)~* Patients with metastases~* Prior treatment with a programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor~* Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment~* Patients with primary salivary gland cancers are excluded~* Patients who have had chemotherapy or biological therapy within 4 weeks of registration~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, autoimmune disease requiring systemic steroids, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Patients who are pregnant or breast-feeding~* Patients with known active human immunodeficiency virus (HIV), hepatitis (hep) B, or hep C infection~* Subjects with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (nivolumab, IMRT) (Type: EXPERIMENTAL): Patients receive nivolumab IV over 30 minutes on weeks -2, 0, 2, 4, and 6 and undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).